We are live on ! Find out more
CORV

Correvio Pharma Corp. Ordinary Shares (Canada)
CORV

Delisted

CORV was delisted on the 26th of May, 2020.

31 hedge funds and large institutions have $38.7M invested in Correvio Pharma Corp. Ordinary Shares (Canada) in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

15% more funds holding

Funds holding: 2731 (+4)

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

54% less capital invested

Capital invested by funds: $84.2M → $38.7M (-$45.5M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
31
Holders Change
+4
Holders Change %
+14.81%
% of All Funds
0.77%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
7
Reduced
12
Closed
3
Calls
Puts
Net Calls
Net Calls Change

CORV Hedge Fund Activity: Q3 2017 in Review

31 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) for Q3 2017, worth a combined $38.7M — down 54% from $84.2M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CORV positions and 3 closed out — a net gain of 4 holders — while 7 added to existing stakes and 12 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $4.32M. The largest seller was Putnam Investments, cutting an estimated $4.45M.

  • 31 institutional investors held Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) as of Q3 2017, up from 27 in Q2 2017.
  • Funds reported $38.7M of Correvio Pharma Corp. Ordinary Shares (Canada) stock for Q3 2017, down 54% quarter-over-quarter.
  • 7 funds opened new Correvio Pharma Corp. Ordinary Shares (Canada) positions in Q3 2017 and 3 closed out, a net change of +4 holders.
  • The largest Correvio Pharma Corp. Ordinary Shares (Canada) buyer in Q3 2017 was Stonepine Capital Management, an estimated $4.32M added.
  • The largest Correvio Pharma Corp. Ordinary Shares (Canada) seller in Q3 2017 was Putnam Investments, an estimated $4.45M sold.

Based on aggregated 13F filings for Q3 2017.